The Global Plasminogen Activator Inhibitor Market is estimated to grow at a significant CAGR during the forecast period.  The plasminogen activator system is involved in a wide range of physiological and pathological processes. PAI-1 is a member of the serine protease inhibitors (or serpins) superfamily and the principal inhibitor of tissue-type and urinary-type plasminogen activators, both of which can activate plasminogen. Plasminogen activator inhibitor 1 is the most potent inhibitor of plasminogen activator in plasma (PAI-1). Increased plasminogen activator inhibitor 1 levels may result in excessive tissue-plasminogen activator blocking, resulting in reduced clot breakdown and, eventually, an undesirable blood clot.  In rare instances, high levels of plasminogen activator inhibitor 1 have been discovered to be an inheritable trait.

The market of plasminogen activators inhibitors is expanding due to the rising prevalence of chronic diseases. Furthermore, government initiatives to improve healthcare facilities, a focus on research, and increased research funding all contribute to the market for plasminogen activators inhibitors rising. Due to an increase in the number of pipeline medications for treating wounds and thrombosis, the market for plasminogen activator inhibitors is expected to expand. For instance,  the Denver Health and Hospital Authority is conducting a clinical phase II study to treat thrombosis and wounds with aspirin and rosuvastatin. The study's purpose is to see how much PAI-1 and tissue plasminogen activator inhibitor are in the blood after taking medicine. The study started in February 2017 and will be completed in December 2021.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segments Covered

o By Product Type

o By Application

• Regions Covered

o North America

o Europe

o Asia-Pacific

o Rest of the world

• Competitive Landscape: Bayer AG, D-Pharm Ltd, GlaxoSmithKline, IntechOpen, Jazz Pharmaceutical among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Plasminogen Activator Inhibitor Market by Segments

By Product Type,

• Plasminogen Activator Inhibitor Type 1 (PAI-1)
• Plasminogen Activator Inhibitor Type 2 (PAI-2)

By Application,

• Fibrinolysis
• Cardiac Fibrosis
• Post-operative Wound Hematomas

Global Plasminogen Activator Inhibitor by Region